Congress of the French-speaking Cellular Haematology Group, Lyon, 21-23 May 2025. Current status and advances in T lymphoid haemopathies (notice n° 1573155)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02292cam a2200193 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20251214025852.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Marchand, Karine |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Congress of the French-speaking Cellular Haematology Group, Lyon, 21-23 May 2025. Current status and advances in T lymphoid haemopathies |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2025.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 68 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Mantle cell lymphoma (MCL) is a rare and aggressive B-cell non-Hodgkin lymphoma, characterized by specific markers such as cyclin D1 and SOX11, along with a well-defined mutational profile. More recently, studies have highlighted the central role of the tumor microenvironment in disease progression and the development of therapeutic resistance, through complex interactions within protective ecosystems. These major advances in the understanding of MCL biology, combined with optimized clinical protocols, have led to a paradigm shift, with prolonged remissions now achievable in some patients following immunochemotherapy. However, the toxicity of such treatments limits their use in frail patients, and a significant proportion of high-risk, refractory cases still lack effective therapeutic options. In this context, the rapid emergence of targeted therapies and immunotherapeutic approaches offers new perspectives by counteracting malignant plasticity and intratumoral heterogeneity. This review first provides an overview of current standards in MCL management, then explores how both intrinsic tumor alterations and interactions with the microenvironment contribute to resistance mechanisms. We then present recent strategies aimed at targeting tumor vulnerabilities within its protective niches. Finally, we discuss the potential of emerging approaches — such as the modulation of epigenetic dysregulation and the restoration of functional lymphoid immunity through modern immunotherapies — as a foundation for future therapeutic options for patients currently facing treatment failure. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | David, Guillaume |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bardet, Valérie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Preudhomme, Claude |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hématologie | 31 | 5 | 2025-11-05 | p. 330-339 | 1264-7527 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/journal-hematologie-2025-5-page-330?lang=en&redirect-ssocas=7080">https://stm.cairn.info/journal-hematologie-2025-5-page-330?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux